Design and synthesis of potent, highly selective vasopressin hypotensive agonists

Journal of Peptide Science : an Official Publication of the European Peptide Society
Stoytcho StoevHazel H Szeto

Abstract

We report here the solid-phase synthesis and vasodepressor potencies of a new lead vasopressin (VP) hypotensive peptide [1(beta-mercapto-beta,beta-pentamethylenepropionic acid)-2-0-ethyl-D-tyrosine, 3-arginine, 4-valine, 7-lysine, 9-ethylenediamine] lysine vasopressin, d(CH(2))(5)[D-Tyr(Et)(2), Arg(3), Val(4), Lys(7), Eda(9)]LVP (C) and 21 analogues of C with single modifications at positions 9 (1-13), 6 (14), 2 (16-20) and combined modifications at positions 6 and 10 (15) and 2 and 10 (21). Peptides 1-13 have the following replacements for the Eda residue at position 9 in C: (1) Gly-NH(2); (2) Gly-NH-CH(3); (3) Ala-NH(2); (4) Ala-NH-CH(3), (5) Val-NH(2); (6) Cha-NH(2); (7) Thr-NH(2); (8) Phe-NH(2); (9) Tyr-NH(2); (10) Orn-NH(2); (11) Lys-NH(2); (12) D-Lys-NH(2); (13) Arg-NH(2). Peptide 14 has the Cys residue at position 6 replaced by Pen. Peptide 15 is the retro-Tyr(10) analogue of peptide 14. Peptides 16-20 have the D-Tyr(Et) residue at position 2 in C replaced by the following substituents: D-Trp (16); D-2-Nal (17); D-Tyr(Bu(t))(18); D-Tyr(Pr(n)) (19); D-Tyr(Pr(i)) (20). Peptide 21 is the retro-Tyr(10) analogue of peptide 20. C and peptides 1-21 were evaluated for agonistic and antagonistic activities in in vivo vasopressor ...Continue Reading

References

Oct 16, 1992·Journal of Medicinal Chemistry·M ManningW H Sawyer
Feb 11, 1991·Journal of Medicinal Chemistry·G FlouretL Wilson
Aug 1, 1989·The Journal of Clinical Investigation·A T HirschM A Creager
Feb 1, 1973·Journal of Medicinal Chemistry·J D Glass, V Du Vigneaud
Dec 3, 1968·Journal of Chromatography·M ManningJ W Baxter
Feb 1, 1967·Journal of the American Chemical Society·M Bodanszky, N J Williams
Nov 1, 1967·Journal of Medicinal Chemistry·H Schulz, V du Vigneaud
Sep 13, 1967·Journal of the American Chemical Society·G W AndersonF M Callahan
Nov 1, 1984·Circulation Research·Z S KatusicP M Vanhoutte
Jan 1, 1982·Journal of Medicinal Chemistry·M ManningW H Sawyer
Jun 1, 1981·Journal of Medicinal Chemistry·M ManningW H Sawyer
Jan 1, 1997·Journal of Peptide Science : an Official Publication of the European Peptide Society·M ManningW Y Chan
Feb 23, 1999·Advances in Experimental Medicine and Biology·W Y ChanM Manning
Mar 11, 1999·Journal of Receptor and Signal Transduction Research·M ManningW Y Chan
May 14, 1999·Journal of Peptide Science : an Official Publication of the European Peptide Society·S StoevW Y Chan
Dec 10, 1999·Journal of Peptide Science : an Official Publication of the European Peptide Society·M ManningW Y Chan
May 31, 2003·Canadian Journal of Physiology and Pharmacology·Ming YuJ Robert McNeill
Dec 1, 1952·British Journal of Pharmacology and Chemotherapy·J DEKANSKI
Nov 5, 2004·Naunyn-Schmiedeberg's Archives of Pharmacology·Reza Tabrizchi, Carol Ann Ford
May 10, 2005·Journal of Peptide Science : an Official Publication of the European Peptide Society·Maurice ManningClaude Barberis
Sep 1, 1947·British Journal of Pharmacology and Chemotherapy·H O SCHILD

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.